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ABSTRACT
Objective To compare the strengths and limitations of
cardiovascular risk scores available for clinicians in
assessing the global (absolute) risk of cardiovascular
disease.
Design Review of cardiovascular risk scores.
Data sources Medline (1966 to May 2009) using
a mixture of MeSH terms and free text for the keywords
‘cardiovascular’, ‘risk prediction’ and ‘cohort studies’.
Eligibility criteria for selecting studies A study was
eligible if it fulﬁlled the following criteria: (1) it was
a cohort study of adults in the general population with no
prior history of cardiovascular disease and not restricted
by a disease condition; (2) the primary objective was the
development of a cardiovascular risk score/equation that
predicted an individual’s absolute cardiovascular risk in
5e10 years; (3) the score could be used by a clinician to
calculate the risk for an individual patient.
Results 21 risk scores from 18 papers were identiﬁed
from 3536 papers. Cohort size ranged from 4372
participants (SHS) to 1591209 records (QRISK2). More
than half of the cardiovascular risk scores (11) were from
studies with recruitment starting after 1980. Deﬁnitions
and methods for measuring risk predictors and outcomes
varied widely between scores. Fourteen cardiovascular
risk scores reported data on prior treatment, but this was
mainly limited to antihypertensive treatment. Only two
studies reported prior use of lipid-lowering agents. None
reported on prior use of platelet inhibitors or data on
treatment drop-ins.
Conclusions The use of risk-factor-modifying
drugsdfor example, statinsdand disease-modifying
medicationdfor example, platelet inhibitorsdwas not
accounted for. In addition, none of the risk scores
addressed the effect of treatment drop-insdthat is,
treatment started during the study period. Ideally, a risk
score should be derived from a population free from
treatment. The lack of accounting for treatment effect
and the wide variation in study characteristics, predictors
and outcomes causes difﬁculties in the use of
cardiovascular risk scores for clinical treatment decision.
INTRODUCTION
For many years, the Framingham cardiovascular
risk equation has been the preferred method of
cardiovascular risk assessment. However, in
February 2010, the National Institute for Health
and Clinical Excellence (NICE) announced that the
Framingham equation should be considered as just
one of several acceptable methods.
1 The same
guideline included a systematic review, which
found 110 different cardiovascular risk-scoring
methods. Clinicians are now able and expected to
select, from these 110 cardiovascular risk scores,
one that is appropriate for their patients. How
should they decide which one is appropriate?
Despite guidelines advocating the use of cardio-
vascular risk scores to calculate global risk instead
of focusing on single risk modiﬁcation, adoption of
cardiovascular risk scores has been slow.
1 2 One
survey in three countries showed that only 48% of
physicians regularly use cardiovascular risk scores.
3
In another survey in six European countries, 85% of
respondents recognised the importance of global
risk assessment; yet, the majority (62%) used
a subjective assessment of cardiovascular risk rather
than speciﬁc risk calculators in practice.
4 Subjective
risk assessment often disagrees with assessment by
cardiovascular risk scores.
35Doctors who use
cardiovascular risk scores can rate individual risk
factors more accurately
6 and are more likely to
correctly prescribe treatment in given scenarios
than non-users.
3
Why don’t doctors use cardiovascular risk scores
in practice? Many physicians do not trust the
validity of the risk scores
7 and believe their own
estimation to be more accurate.
3 Another reason
may simply be that there is too much choice. The
Framingham risk equations were ﬁrst published in
1976.
8 Since then, many other cohort studies have
developed their own equations such as PROCAM,
9
SCORE
10 and QRISK.
11 These cohort studies
differ signiﬁcantly in terms of study population
characteristics, risk predictors and outcomes.
12
Cardiovascular risk scores measure baseline risk
factors to predict future cardiovascular morbidity
What is already known on this subject
< Guidelines advocate the use of cardiovascular
risk scores to calculate global risk instead of
focusing on single risk modiﬁcation.
< Healthcare providers in the UK are expected to
select a cardiovascular risk score appropriate for
their requirements from the many existing risk
assessment tools with the recent change in the
NICE guidelines.
What this study adds
< The existing risk scores vary widely in terms of
study characteristics, predictors and outcomes.
< These cohort studies have not taken into account
the effect of treatment on the study population and
will therefore underestimate cardiovascular risk.
< Additional material is
published online only. To view
this ﬁle please visit the journal
online (http://heart.bmj.com).
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Systematic reviewand mortality, but most do not account for changes in treatment
during the years of follow-up. Failure to adjust for such treat-
ment effects will cause cardiovascular risk scores to systemati-
cally underestimate predicted risk. This problem is greater for
more recent studies with the progressive increase in the use of
effective medication for blood pressure and lipids over the past
20e30 years.
13 14
We aimed to review the strengths and limitations of current
cardiovascular risk scores, to assess how these may impact on the
classiﬁcation of patients’ risk of cardiovascular disease, and to
identify the scores that may be most appropriate for use in clinical
care.
METHODS OF REVIEW
Objectives
The objective of this review is to assess the strengths and
limitations of cardiovascular risk scores available to clinicians for
the assessment of global or absolute risk of cardiovascular
disease. A particular focus was on how the risk scores dealt with
the effects of treatment during follow-up.
Search methods for identiﬁcation of studies
We searched Medline (1966 to May 2009) using a mixture of
MeSH terms and free text for the keywords ‘cardiovascular’, ‘risk
prediction’ and ‘cohort studies’. To identify other studies that
answered our question, we also used our own literature ﬁles,
previous reviews of cardiovascular scores, and citation tracking.
A study was eligible if it fulﬁlled the following criteria: (1) it
was a cohort study of adults in the general population with no
prior history of cardiovascular disease and not restricted by
a disease condition; (2) the primary objective was the develop-
ment of a cardiovascular risk score/equation that predicted an
individual’s absolute cardiovascular risk in 5e10 years; and (3)
the score could be used by a clinician to calculate the risk for an
individual patient.
Identifying studies
We screened the titles and abstracts of all retrieved records to
identify exclusions. Full copies or reprints of records not
excluded were then assessed to determine if they met with the
inclusion criteria for the review. Any disagreements were
resolved through discussion.
Data extraction
Two reviewers, LSM and JD, appraised and selected the studies,
then extracted information from each study for analysis. Infor-
mation extracted included study demographics, outcomes,
predictors and treatment effect.
Analytical methods
Study methods were assessed using criteria adapted from Wasson
et al
15 and Royston et al,
16 including sampling, predictors, follow-
up, outcomes, data quality and performance of the rule.
RESULTS
A total of 3536 papers were retrieved after removal of duplicates
from records identiﬁed through the Medline search and other
sources. Figure 1 shows the PRISMA ﬂow diagram. The PRISMA
statement and review protocol are available online as supple-
mental material.
Description of studies
We identiﬁed 21 risk scores eligible for the review (table 1) from
18 papers. Five were from Framingham,
8 17e19 three from the
Munster group (PROCAM)
92 0and ARIC (Atherosclerosis
Risk in Communities),
21 22 two each from QRISK
11 23 and
Reynolds,
24 25 and one each from the Scottish Heart Health
Extended Cohort,
26 Strong Heart Study,
27 USA-PRC (People’s
Republic of China Collaborative Study of Cardiovascular
Epidemiology)
28 and NHEFS (National Health and Nutrition
Examination Survey NHANES 1 Epidemiologic Follow-up
Study).
29 Some risk scores used multiple cohorts: SCORE
10 was
derived from a pool of 12 European cohorts, and Progetto
CUORE
30 from a pool of Italian cohorts. Twelve are from North
America, eight are European, and one from China.
Figure 2 shows a timeline chart of the reviewed cohort studies
and the introduction of several drugs.
13 14
Analytical methods
Table 2 compares the analytical methods of the reviewed risk
scores.
The areas in which most of the risk equations did poorly were:
(1) reporting loss to follow-up; (2) percentage of missing values;
and (3) blind assessment of outcomes.
Risk predictors and their deﬁnitions
The ﬁnal number of risk predictors ranged from ﬁve (PROCAM
stroke) to 15 in QRISK 2 (table 3). Selection of predictors was
mostly by signiﬁcance testing (table 2). All scores included age,
gender, blood pressure and smoking, and most included lipids
and diabetes. Lipid levels were not used in the non-laboratory
model of the 2008 Framingham risk score, the PROCAM 2007
risk equation for stroke, or the NHEFS risk score. Diabetes,
glucose intolerance or HbA1c level was a predictor for all except
the European SCORE. Other risk predictors included by some
scores were left ventricular hypertrophy, antihypertensive
medication use, body mass index, ethnicity, family history,
socioeconomic status, medical diseases, biomarkers (hsCRP and
albuminuria) and physical activity.
Deﬁnitions for risk predictors differed from score to score. In
the original Framingham cohort, diabetes was deﬁned as
a random blood glucose measurement $150 mg/dl (8.3 mmol/l)
or treatment with insulin or oral hypoglycaemics. In the
Figure 1 PRISMA ﬂow diagram.
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Systematic reviewFramingham Offspring cohort, this deﬁnition was broadened to
a fasting plasma glucose level $140 mg/dl (7.7 mmol/l) or
treatment requirement.
18 This in turn differs from the current
deﬁnition used by the World Health Organization (WHO) of
fasting plasma glucose $126 mg/dl (7.0 mmol/l).
31 Hence,
patients with fasting plasma glucose between 126 and 150 mg/dl
(7e8.3 mmol/l) would be classed as non-diabetics by the ﬁrst
Framingham score. Systolic blood pressure measurement
Table 1 Description of the studies
Study Country Population Sample size Age % Female Recruitment period
Framingham 1976 USA Population cohort 5209 35e64 55 1948e1952
Framingham 1991 USA Population cohort
(original + offspring)
5573 30e74 54 1968e1971;
1971e1975
Framingham 1998 USA Population cohort
(original + offspring)
5345 30e74 53 1968e1971;
1971e1975
Framingham 2008 USA Population cohort
(original + offspring)
8491 30e74 53 1968e1971;
1971e1975;
1984e1987
PROCAM 2002 Germany Occupational cohort 5389 35e65 0 1979e1985
PROCAM 2007
CHD Germany Occupational cohort 26975 20e75 32 1978e1995
Stroke Occupational cohort 8130 35e65 27 1978e1995
SCORE 2003 Europe Pooled dataset of
cohort studies
205178 45e64 43 1967e1991
ARIC 2003 USA Population cohort 14054 45e64 57 1987e1989
Progetto CUORE 2004 Italy Pooled dataset of
cohort studies
20647 35e69 64 1983e1997
Strong Heart Study 2006 USA Population cohort -
American Indian
4372 45e74 61 1989e1991
USA-PRC 2006 China Population cohort 9903 39e59 51 1983e1984
ASSIGN 2007 UK Population cohort 13297 30e74 51 1984e1995
Reynolds women 2007 USA Women’s Health
Study trial subjects
16400 45+ 100 1992e1995
Reynolds men 2008 USA Physician Health
Study trial subjects
10724 50e80 0 1995e1997
Personal Heart 2007 USA Population cohort 14343 45e64 57 1987e1989
QRISK 2007 UK Electronic medical database 1283174 35e74 50 1995e2007
QRISK2 2008 UK Electronic medical database 1535583 35e74 50 1993e2008
NHEFS 2008 USA Population cohort 6186 25e74 54 1971e1975
Figure 2 Timeline of studies.
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Systematic reviewmethods included averages taken from two readings
(Framingham, Progetto CUORE, ASSIGN), average of last two of
three readings (ARIC, SHS, NHEFS), average of three readings
(USA-PRC) and second reading taken from two readings
(PROCAM). For some scores, the measurement method was ill
deﬁned: self-report (Reynolds Study), general practitioner record
(QRISK studies) or a previous diagnosis of hypertension
(Personal HEART), to not being stated (SCORE).
Outcomes predicted
The outcomes predicted differ widely between the risk scores
(table 4), ranging from general cardiovascular risk to speciﬁc
disease outcomes. Almost all scores predict myocardial infarc-
tion and death from coronary heart disease. Only 12 of the 21
scores included cerebrovascular events. SCORE only predicts
fatal cardiovascular events.
Methods to assess outcome events also differed. The SCORE
and ASSIGN scores used hard outcomes with diagnostic codes
such as ICD 9/10 codes. ‘Hard outcomes’ can be deﬁned as
irrevocable events
32 that have permanent consequences, such as
myocardial infarction and death, as opposed to ‘soft events’,
such as hospitalisation for angina. The Framingham studies
included a broader composite of hard and soft end points.
Diagnostic criteria for outcomes in Progetto CUORE and the
USA-PRC cohorts followed the WHO-MONICA Study
(WHOeMONItoring trends and determinants in CArdiovas-
cular disease project).
28 30 Expert panels reviewed medical
records and hospital notes in the Framingham studies, PROCAM
scores, ARIC, SHS, Reynolds studies and the NHEFS. QRISK1
and 2 used general practice electronic recorded diagnosis or death
certiﬁcates linked to the computer system.
Adjustment for treatment effects
Methods used to adjust for the effect of medication were absent
or weak (table 5). The effect of treatment is not fully assessed or
adjusted for by any of the reviewed risk scores. Treatment effect
includes (1) that which occurs by risk factor modiﬁcation (eg,
blood pressure-lowering medication), (2) that which works
independently of risk factors (eg, platelet inhibitors such as
aspirin), and (3) that which works by both means (eg, statins).
Twelve of the cardiovascular risk score studies (Framingham
1998, Framingham 2008, ARIC, Progetto CUORE, SHS, USA-
PRC, Reynolds 2007, Reynolds 2008, Personal Heart, QRISK1,
QRISK2, and NHEFS) reported data on prior treatment, but this
was mainly limited to antihypertensive treatment. Only seven
(Framingham 2008, ARIC, Progetto CUORE, SHS, QRISK1,
QRISK2 and NHEFS) included the use of antihypertensive drugs
as a risk predictor. The Reynolds studies were the only ones to
report prior use of lipid-lowering agents. None of the studies
reported on the prior use of platelet inhibitors.
Two treatment effects need to be considered: (1) prior treat-
ment (started before enrolment in the study) and (2) subsequent
Table 3 Predictors
Age Sex Smoking SBP DBP
Sr. 
Chol
HDL Tg Diabetes LVH
Antihpt 
med.
BMI Ethnicity
Family 
hx
SCE 
status
Rh 
arthritis
Chronic 
renal ds
Atrial fib.
Bio-
markers
Physical 
activity
No of predictors/ 
no of candidate 
predictors
Framingham 
1976 Years M/F Y/N
average of 2 
readings
TC
RBS ≥ 
8.3 / 
urine +
ECG-
LVH
7/19+
Framingham 
1991 Years M/F Y/N
average of 2 
readings
SBP 
alternative
TC
Original 
RBS 
≥8.3; 
Offspring 
FBS ≥7.7
ECG-
LVH
8/19+
Framingham 
1998 Years M/F Y/N
average of 2 
readings
SBP 
alternative
TC 
or 
LDL
7/19+
Framingham 
2008 
General Years M/F Y/N
average of 2 
readings
TC
Original 
FBS≥7.7; 
Offspring 
FBS≥6.9
Y/N 8/19+
Non-
Lab
Years M/F Y/N
average of 2 
readings
Y/N 3 groups 7/19+
PROCAM 
2002
Years NA Y/N
2 readings -
2nd taken
LDL
FBS ≥ 
6.6
Y/N 8/57
PROCAM 
2007 CHD Years M/F Y/N
2 readings -
2nd taken
LDL
FBS ≥ 
6.6
Y/N 9/57
Stroke Years M/F Y/N
2 readings -
2nd taken
FBS ≥ 
6.6
5/57
SCORE 2003 Years M/F Y/N Not stated TC or ratio  5/5
ARIC 2003
Years M/F Y/N
average of 
last 2 of 3 
readings
TC FBS≥ 7.0 Y/N
2 
groups
9/27
Progetto 
CUORE 2004
Years M/F Y/N
average of 2 
readings
TC
FBS ≥ 
7.0
Y/N 8/19 
SHS 2006
Years M/F Y/N
average of 
last 2 of 3 
readings
TC 
or 
LDL
FBS≥ 7.0 Y/N albuminuria 9/14 
USA-PRC 
2006
Years M/F Y/N
average of 3 
readings
TC FBS≥ 7.0 2 groups 7/7
ASSIGN 2007
Years M/F
Y/N plus 
cigs/day
average of 2 
readings
TC
Not 
stated
Y/N SIMD 9/11+
Reynolds 
women 2007
Years NA Y/N self reported TC
HbA1c if 
diabetic
Y/N hsCRP 8/35
Reynolds 
men 2008 Years NA Y/N self reported TC
excluded 
at 
baseline
Y/N hsCRP 8/8
Personal 
Heart 2007
men Years NA
Y/N/ 
Former
previous 
diagnosis of 
hypertension
previous diagnosis 
of 
hypercholesteraemia
previous 
diagnosis 
of 
diabetes
Y/N
often/ 
sometimes/ 
never
7/10
women Years NA
Y/N/ 
Former
previous 
diagnosis of 
hypertension
previous diagnosis 
of 
hypercholesteraemia
previous 
diagnosis 
of 
diabetes
2 groups 6/10
QRISK 2007
Years M/F Y/N GP record
TC/HDL 
ratio
excluded 
at 
baseline
Y/N
recorded 
value
Y/N Townsend 9/11
QRISK 2 
2008
Years M/F Y/N GP record
TC/HDL 
ratio
recorded 
diagnosis
Y/N
recorded 
value
9 
groups
Y/N Townsend
recorded 
diagnosis
recorded 
diagnosis
recorded 
diagnosis
14/14
NHEFS 2008
Years M/F Y/N
average of 
last 2 of 3 
readings
previous 
diagnosis 
of 
diabetes
4 groups 6/6
Shaded areas, Predictors not included in risk score; SBP, systolic blood pressure; DBP, diastolic blood pressure; Sr. Chol, serum cholesterol; HDL, high density lipoprotein cholesterol;
Tg, triglycerides; LVH, left ventricular hypertrophy; Antihpt med, antihypertensive medication; BMI, body mass index; Family hx, family history; SCE, socioeconomic; Rh arthritis, rheumatoid
arthritis; Atrial ﬁb, atrial ﬁbrillation; No, number; M, male; F, female; Y, yes; N, no; TC, total cholesterol; RBS, random blood sugar; FBS, fasting blood sugar; LDL, low density lipoprotein
cholesterol; Non-lab, non-laboratory; NA, not applicable; Cigs, cigarettes; SIMD, Scottish Index of Multiple Deprivation; HbA1c, haemoglobin A1c; hsCRP, high sensitivity c-reactive protein;
GP, general practice.
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None of the risk scores addressed the effect of treatment
drop-ins. For early studies, such as the older Framingham Study,
this may be minimal. Recent cohorts such as QRISK may have
had more than half of their study population receiving treat-
ment with their blood pressure under control (see NHANES
data
33e37 in ﬁgure 2).
DISCUSSION
For users of cardiovascular risk scores, this review has two main
ﬁndings: that cardiovascular risk scores differ considerably in
terms of population, predictors and outcomes, which may not
match those used by clinicians, and that treatment ‘drop-in’ is
poorly accounted for by most rules.
Whichever risk equation they choose, clinicians should know
which outcomes are predicted. As the outcomes predicted differ
signiﬁcantly, the risk scores are not interchangeable. For example,
the Framingham risk scores predict a broad range of cardiovas-
cular events (including cerebrovascular events), whereas SCORE
only predicts fatal cardiovascular events. The Framingham Study
risk scores have been criticised for the inclusion of ‘soft’
(subjective) outcomes such as angina,
10 although the
Framingham investigators argue that such outcomes estimate
the total cardiovascular disease burden
19 and are clinically
important to both patient and doctor. Revascularisation inter-
ventions may also be criticised as being subjective.
Time is a major obstacle to the use of risk scores by physi-
cians
4; obtaining more information from a patient will
further decrease the use of risk calculators. Of the risk scores,
QRISK2 had the most predictors, which included disease
conditions such as atrial ﬁbrillation and chronic renal disease.
QRISK2 score is designed to use data in the patient’s electronic
health record, with imputed values for missing data. However,
the proportion with missing data for these factors in the deri-
vation cohorts was substantial (>70% for ethnicity; >60% for
cholesterol).
23
The second limitation is that the effect of treatment has not
been considered fully by any of the reviewed risk scores. Treat-
ment decreases the true effect of risk factors on outcomes,
38 39 as
illustrated by ﬁgure 3. The combined effects of risk reduction
due to treatment can be as much as 50%.
40 If 25% of the
population started treatment during follow-up, it would mean
Table 4 Outcomes
h t a e D s e m o c t u O
from 
CHD 
MI Ischaemic 
stroke 
Haemorrhagic 
stroke 
TIA Angina 
pectoris 
Revascularisation 
interventions 
PAD Hypertensive 
CCF 
Framingham 1976  General 
CVD 
events 
I       
Framingham 1991  CHD 
Framingham 1998  CHD 
Framingham 2008  General 
CVD 
events 
I                
PROCAM 2002  CHD 
PROCAM 2007  CHD 
Cerebral 
ischaemic 
events 
SCORE 2003  Fatal 
CVD 
events 
I F  F     F  F 
ARIC 2003  CHD 
Progetto CUORE 2004  CVD 
events  I          
SHS 2006  CHD 
USA-PRC 2006  CVD 
events I       
ASSIGN 2007  CVD  I A  A  A  A A     
Reynolds women 2007  CVD 
events  I       
Reynolds men 2008  CVD 
events  I       
Personal Heart 2007  CHD 
QRISK 2007  CVD 
events  I             
QRISK 2 2008  CVD 
events  I       
NHEFS 2008  CVD 
events  I       
Shaded areas, outcomes not included in risk score; I, includes other fatal CVD; F, only if fatal; A, only if admitted; CHD, coronary heart disease; MI, myocardial infarct; TIA, transient ischaemic
attack; PAD, peripheral artery disease; CCF, congestive cardiac failure; CVD, cardiovascular disease.
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in the high-risk groups, who are more likely to be treated. These
differences are similar to those found between QRISK 2 and
Framingham (11.6%), which was obtained in a recent validation
study of QRISK 2.
41
Ideally, a cardiovascular risk score to determine the risk of
a cardiovascular event and to stratify patients for risk factor
modiﬁcation should be derived in a population receiving no
treatment at the start of and during the study. Such an ideal
study is not tenable or ethical. We know of three possible
Table 5 Treatment effect
k s i R
Predictors  t n e m t a e r T r o i r P Treatment during the 
study 
Measurement Follow-up Treatment 
exclusions 
Treatment 
assessed 
Adjustment 
methods 
Trial 
medication 
Treatment 
drop ins 
Framingham 1976  Single  2 yearly exams 
Framingham 1991  Single 2-4  yearly  exams 
Framingham 1998  Single 2-4  yearly  exams  Antihpt 
Framingham 2008 
Single 2-4  yearly  exams  Antihpt 
SBP if treated 
and SBP if not 
treated included 
as predictor 
PROCAM 2002  Single  2 yearly 
questionnaire 
PROCAM 2007  Single  2 yearly 
questionnaire 
SCORE 2003 
Single  Varies between 
cohorts 
ARIC 2003 
Single 
3 yearly exams. 
Outcomes from 
yearly interviews 
Antihpt  Included as 
predictor 
Progetto CUORE 
2004  Single  Varies between 
cohorts  Antihpt  Included as 
predictor 
SHS 2006 
Single 
3-4 yearly exams. 
Outcomes from 
yearly interviews 
and records 
Antihpt  Included as 
predictor 
USA-PRC 2006 
Single 2-4  yearly  exams  Antihpt and 
OCP  * 
ASSIGN 2007 
Single 
None for pred. 
Outcomes from 
record linkage 
Reynolds women 
2007 
Single 
None for pred. 
Outcomes from 6-
12 monthly 
questionnaire 
Several 
Antihpt, lipid 
lowering, 
hormone 
therapy, 
vitamins 
Aspirin, 
vitamin E 
Reynolds men 
2008 
Single 
None for pred. 
Outcomes from 
annual 
questionnaire 
Vitamins  Antihpt, lipid 
lowering 
Beta 
carotene, 
vitamin C, 
vitamin E, 
multivitamins 
Personal HEART 
2007  Single 
3 yearly exams. 
Outcomes from 
yearly interviews 
Antihpt 
QRISK 2007 
Single 
None for pred. 
Outcomes from 
record linkage 
Antihpt  Included as 
predictor 
QRISK 2 2008 
Single 
None for pred. 
Outcomes from 
record linkage 
Those on 
statins   Antihpt  Included as 
predictor 
NHEFS 2008 
Single 
None for pred. 
Outcomes from 5 
to >10 yearly 
survey interviews 
Antihpt 
Included as 
predictor in 
model but not 
risk chart 
Shaded areas, information not reported; Antihpt, antihypertensive medication; SBP, systolic blood pressure; pred, predictors.
*Corrected for change in risk factors by factoring in changes at midpoint of follow-updthat is, 1993/1994.
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Systematic reviewsolutions. First, we could favour the use of older studies, when
less aggressive treatment occurred. Second, treatment uptake
could be monitored and appropriate adjustments such as the
application of a penalised Cox model made to account for the
effect of treatment.
42 Until such studies have been performed,
study cohorts where there is minimal treatment drop-in during
follow-up should be preferred. Alternatively, to minimise treat-
ment drop-in, we could study cohorts with much larger
numbers over much shorter periods (Rod Jackson, personal
communication).
We have not addressed how risk scores may change over time.
However, a common misconception is that the strength of the
risk scores change with population health status. Changes in the
prevalence of a risk factor should not change the underlying
relationship of a risk predictor to a disease outcome. For example,
lower rates of smoking will not change the RR reduction due to
smoking. Study participants may have changed their risk behav-
iourdfor example, stopped smoking during the study. However,
that is another treatment effect and should ideally be measured.
The lack of accounting for treatment makes the use of most
cardiovascular risk scores for treatment decisions problematic.
We need to examine how doctors use cardiovascular risk scores
in clinical practice. If the aim is to discuss with patients the risk
of remaining untreated, then the use of the majority of these risk
scores would be incorrect.
Strengths and weaknesses of the study
The review was limited to studies in which participants had no
previous history of cardiovascular disease and excluded those
who were restricted to a disease condition. A prior diagnosis of
cardiovascular disease or a disease such as diabetes raises the
patient into the high-risk category, removing the need for risk
scoring. This has also been advocated by the NICE guidelines,
which states that risk equations should not be used for those
with a previous history of cardiovascular disease or other high-
risk diseases such as diabetes.
1 Furthermore, the majority of
these patients would have received treatment, potentially
altering study outcomes.
This is a detailed review with a clear and focused question and
explicit methodology. The review is particularly relevant to the
recent modiﬁcation of the NICE guidelines and offers the most
up-to-date comparison of available cardiovascular risk scores.
It has also identiﬁed a major gap in risk assessment studies,
namely, the effect of treatment.
Strengths and weaknesses in relation to other studies,
discussing particularly any differences in results
The 2005 review by Beswick et al
43 included in the appendix of
the NICE guidelines identiﬁed 110 studies, with 70 meant
speciﬁcally for application in primary prevention. The difference
in the number of studies identiﬁed is due to their wider inclusion
criteria, which included studies restricted to a disease condition,
studies that had participants with prior cardiovascular disease,
studies that were recalibrations or modiﬁcations of the original
cohort study, studies that did not use absolute risk scoring, and
studies where the duration of prediction was not speciﬁed. More
recent studies such as QRISK and Reynolds scores are not
included, as their search concluded in April 2005.
Meaning of the study: possible mechanisms and implications for
clinicians or policymakers
The recent change in the NICE guidelines has major implica-
tions for clinical practice. Selecting an appropriate risk score is
likely to be difﬁcult because of the wide variation in available
risk scores. This review has attempted to address the problem by
comparing features of all the cardiovascular risk scores.
Unanswered questions and future research
This review did not address the effectiveness or accuracy of the
cardiovascular risk scores, which would require a review of
validation studies instead of the original cohort studies. The
reviews by Beswick et al and Brindle et al
44 have tried to assess
this, but do not include the more recent studies. However, it
should be pointed out that any validation study of risk scores
might also suffer the same problem of treatment drop-in, which
would attenuate the true cardiovascular risk. Researchers should
also attempt to address the effect of treatment in future studies
in this ﬁeld by collecting data on treatment at the start and
during the course of cohort studies, as this will impact on the
ﬁnal outcomes.
Authors’ conclusions
Implications
These results show that there are substantial differences in
the available cardiovascular risk scores in terms of study
characteristics, predictors and outcomes. The effect of treatment
on the study population has not been taken into account by
these cohort studies. Further study is required for the translation
of such research into clinical practice.
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